Cellular Approaches is a biotechnology company focused on advancing new innovations in innate immunity to address unmet needs in medicine. Building on recent innovations in cellular biology, Cellular Approaches is developing a proprietary, first-in-class pipeline of innate immunity cell-based therapeutics for the treatment of infectious disease, autoimmunity, neurodegeneration, and aging.
Sanford J. Madigan, Ph.D. joined Cellular Approaches as the Chief Business Officer in 2017. ...Read More
Dr. Madigan is an experienced biotechnology executive bringing over 20 years of industry experience to his role as Senior Vice President at COI. Dr. Madigan has been instrumental in venture financings, licensing founding and value-added technologies, developing infrastructure, establishing strategic direction, negotiating strategic partnerships and corporate acquisitions. At COI, Dr. Madigan is a founder of Silarus, Iron Horse and PDI. He also currently serves as CEO of Sova Pharmaceuticals, an Avalon Ventures IX portfolio company and is the executive founder and CEO of Ankasa Regenerative Therapeutics, an Avalon Ventures X portfolio company for which he raised a $19M Series A round. Prior to these roles, Dr. Madigan served in various venture-backed biotechnology companies; participating as a founder and/or senior manager in Strategic Enzyme Applications, BioVerdant, Nereus Pharmaceuticals and SIBIA Neurosciences (acquired by Merck) and the Avalon Ventures founded companies Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen) and X-Ceptor Therapeutics (acquired by Exelixis).
Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies. He received his Ph.D. in Genetics and his B.S. in Biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.
Deborah G. Nguyen, PhD, joined Cellular Approaches as the Vice President of Research in 2017. Over the last decade, she has focused...Read More
Deborah G. Nguyen, PhD, joined Cellular Approaches as the Vice President of Research in 2017. Over the last decade, she has focused on enabling drug discovery and development in both pharma and biotech environments. After earning her PhD studying macrophage/HIV interactions, she spent ten years at the Genomics Institute of the Novartis Research Foundation (GNF) leading programs in all phases of the pre-clinical drug discovery process from target validation to pre-clinical candidate nomination, with a focus on autoimmunity / inflammation and metabolic disease. She most recently served as Senior Director of Research and Development at Organovo, using the company’s proprietary bioprinting platform to create more predictive pre-clinical tissue models. Those efforts led to the successful launch of two patented engineered tissue products and subsequent peer reviewed publications describing their utility.
Deb received her PhD from the Johns Hopkins School of Medicine and a BS in Biochemistry from California State University, Los Angeles.
Jay Lichter, Ph.D. is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in ...Read More
Jay Lichter, Ph.D. is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research, and business development. Throughout his career, Dr. Lichter has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech companies and identifying the commercial potential of scientific discoveries at their earliest stages. Dr. Lichter is the inventor on over 260 patents and patent applications for several Avalon portfolio companies, including more than 60 issued patents. Dr. Lichter has been either directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $3 billion.
Dr. Lichter led Avalon XI investments in Fortis Therapeutics and T-Rx and led Avalon X investments in AristaMD, Otonomy (NASDAQ: OTIC), SynthoRx, as well as the following investments in Sitari, Silarus, Thyritope, CadheRx, Adrenergics, Calporta, Iron Horse & PDI as part of the $495 MM strategic collaboration with GlaxoSmithKline. Dr. Lichter led Avalon investments in Afraxis, Carolus, Otonomy, Zacharon, RQx, Sova and Aratana (NASDAQ: PETX). He currently serves as a member of the board of directors for Avelas, AristaMD, SynthoRx, COI Pharmaceuticals, Otonomy, Fortis Therapeutics, T-Rx and Sova.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.
Tighe Reardon joined Avalon in 2014. Mr. Reardon has over 18 years of senior finance and technical tax experience ranging from ...Read More
Tighe Reardon joined Avalon in 2014. Mr. Reardon has over 18 years of senior finance and technical tax experience ranging from start-ups to large public companies. He has supported over $2 billion of public debt financings and re-financings and was instrumental in the finance, tax and treasury integration of multiple business acquisitions which totaled in excess of $750 million. Mr. Reardon is also CFO of COI Pharma and all portfolio companies housed at COI Pharma. Mr. Reardon is on the Board of Directors of all companies in the GSK collaboration as well as Arista MD and Cellular Approaches.
Prior to joining Avalon, Mr. Reardon was the Senior Vice President of Tax and Treasury at DJO Global, Inc., a $1.2 billion multinational medical device company owned by Blackstone, Inc. (NYSE:BX). Additionally, Mr. Reardon acted as the Director of Taxation for Relational Investors, LLC, a $7 billion activist fund.
Mr. Reardon began his career at Arthur Andersen LLP. He has a M.S. in taxation and a B.S. in accounting from San Diego State University. He is a Certified Public Accountant in the State of California.
Victor Nizet is a Professor and Vice Chair for Basic Research and Chief of the Division of Host-Microbe Systems & Therapeutics ...Read More
Victor Nizet is a Professor and Vice Chair for Basic Research and Chief of the Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego (UCSD), School of Medicine as well as Professor at UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences. Dr. Nizet received his medical training at Stanford University School of Medicine, completed a Residency and Chief Residency in Pediatrics at Harvard University’s Children’s Hospital in Boston, Massachusetts, and a Fellowship in Pediatric Infectious Diseases at the University of Washington’s Children’s Hospital in Seattle. Dr. Nizet leads a large basic and translational research laboratory focused on discovering virulence factors of leading human bacterial pathogens, elucidating mechanisms of host innate immunity, and novel approaches to infectious disease therapy. Dr. Nizet has authored over 370 peer-reviewed publications, including several in the most prestigious general scientific journals. He has collaborated with several biotechnology interests in developing new antibiotic and immune-based therapies against drug-resistant pathogens. Dr. Nizet’s work has been recognized by an American Heart Association Established Investigator Award, the American Lung Association Career Investigator Award, the American Asthma Foundation Senior Investigator Award, the E. Mead Johnson Award for Research in Pediatrics, and the 2016-17 UCSD Chancellor’s Award for Excellence in Research in Science and Engineering. Dr. Nizet has been elected to the American Society for Clinical Investigation, the Association of American Physicians, and the American Academy of Microbiology. Details of his research program can be found on the laboratory website: http://nizetlab.ucsd.edu
Howard A. Shuman, Ph.D. studies the biology of bacterial pathogens and the origins and mechanisms of virulence determinants ...Read More
Howard A. Shuman, Ph.D. studies the biology of bacterial pathogens and the origins and mechanisms of virulence determinants and intrinsic antibiotic resistance. His lab uses a variety of approaches, including bacterial genetics and genomics, transcriptome studies, and cell biology, to understand how bacteria acquire virulence determinants and deploy them to succeed as pathogens. The most recent publication from the Shuman Lab is: “GigA and GigB are Master Regulators of Antibiotic Resistance, Stress Responses, and Virulence in Acinetobacter baumannii”. A complete list of publications can be found at:
Recent honors and awards include: Lady Davis Visiting Professor, Hebrew University, Jerusalem (2007); Distinguished Seminar Series Speaker, NIAID, Rocky Mountain Laboratory (2008) Fellow, American Association for the Advancement of Science (2009) Karin-Ippen Ihler Memorial Lecturer, Texas A&M Medical School (2010) Lecturer, Howard Taylor Ricketts Symposium, University of Chicago (2011).
Shuman holds a B.S. in Microbiology (honors) from the University of Massachusetts and a Ph.D. in Biological Chemistry from Harvard University. He was a postdoctoral fellow in the Department of Biochemistry and Molecular Biology at Harvard University. He was a Professor in the Department of Microbiology & Immunology at Columbia University in the City of New York from 1982 to 2010. Shuman joined the University of Chicago, Department of Microbiology in 2010.
Lev Becker’s research interests include using proteomics and bioinformatics to investigate the roles of macrophages in atherosclerosis, ...Read More
Lev Becker’s research interests include using proteomics and bioinformatics to investigate the roles of macrophages in atherosclerosis, diabetes, obesity, and sleep disruption in an integrated manner. His studies examine how changes to cellular protein expression patterns manifest in altered functional/phenotypic states. In this regard, complex protein expression patterns have been leveraged for the purposes of identifying coherent protein networks with disease-causing properties, interrogating macrophage/dendritic cell phenotype in vivo, and identifying proteins (or groups of proteins) that mediate specific biological activities.
He was the recipient of the 2012 George M. Eisenberg Foundation for Charities Excellence Award for Pediatrics, as well as the 2008 Young Investigator Award, Third International Symposium–Integrated Biomarkers in Cardiovascular Disease. Becker was a postdoctoral fellow at the University of Washington’s Department of Medicine.
Becker received his PhD in biochemistry from Queen’s University in Canada in 2003 as well as his MSc in 1999. He received his BSc from Queen’s University in 1997.
Becker joined the University of Chicago faculty in 2012.
Dr. Chris Wilson is a senior advisor for the Discovery and Translational Sciences team, having previously served as Director from 2010 to ...Read More
Dr. Chris Wilson is a senior advisor for the Discovery and Translational Sciences team, having previously served as Director from 2010 to 2016. This team seeks to identify, foster and translate fundamental scientific and technological advances into new solutions that can promote global health and wellbeing and help to prevent, diagnose and treat globally important diseases. They collaborate with partners within and outside the foundation to create a more integrated, agile R&D process to address the urgent unmet need for these new solutions.
Before joining the Foundation he was at the University of Washington as Chairman of the Department of Immunology and head of the graduate program in immunology, prior to which he led the Division of Infectious Diseases, Immunology and Rheumatology in the Department of Pediatrics. He has also served on a number of national advisory panels, including the Institute of Medicine Vaccine Safety Review Committee (2001-2004), the National Advisory Council on Child Health and Human Development, NICHD and the National Institutes of Health Advisory Committee to the Director. He currently serves on the National Advisory Allergy and Infectious Diseases Council (NIAID). He is an elected fellow of the American Association for the Advancement of Science. Wilson received a bachelor’s degree from the University of California, Irvine and a medical degree from UCLA. He trained in pediatrics at Boston Children’s Hospital /Harvard Medical School and was a post-doctoral fellow in infectious diseases while performing immunology research at Stanford University.
Dr. Michael Dudley has over 30 years of experience in antiinfective drug research and development, with experience in the discovery, preclinical and clinical stages in both academia and industry. ...Read More
Dr. Michael Dudley has over 30 years of experience in antiinfective drug research and development, with experience in the discovery, preclinical and clinical stages in both academia and industry. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor from a new chemical class (vaborbactam) as the combination product Vabomere™ that advanced from discovery to FDA approval in < 8 years. He has been the principal investigator for ~ $200 million funding from public-private partnerships (e.g., BARDA) to advance antimicrobial agents in development in the US and Europe. Prior to his current position, he held positions of increasing responsibilities at small biotech companies include Microcide, Diversa, and Mpex Pharmaceuticals. He cofounded Rempex Pharmaceuticals that was acquired by the Medicines Company in 2013. Prior to his career in pharmaceutical industry, he held academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted research in infectious disease, including important clinical studies (Phase I-IV) and pioneering work in describing PK-PD approaches and characterization of several classes of antibacterial, antifungal, and antiviral agents. Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, and at international meetings on infectious diseases. He has served as a consultant on several advisory boards for pharmaceutical industry on antiinfective use and development and as an Editor for Antimicrobial Agents and Chemotherapy. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (Pharm.D.) from the University of California San Francisco (UCSF) in 1980, completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.